Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ Owens & Minor Inc. (OMI) Stock Forecast & Price Prediction United States | NYSE | Healthcare | Medical Distribution
$3.36
+0.03 (0.90%)Did OMI Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if Owens & Minor is one of their latest high-conviction picks.
Based on our analysis of 16 Wall Street analysts, OMI has a neutral consensus with a median price target of $5.50 (ranging from $4.00 to $7.00). The overall analyst rating is Buy (6.0/10). Currently trading at $3.36, the median forecast implies a 63.7% upside. This outlook is supported by 1 Buy, 2 Hold, and 2 Sell ratings.
The most optimistic forecast comes from Kevin Caliendo at UBS, projecting a 108.3% upside. Conversely, the most conservative target is provided by Kevin Caliendo at UBS, suggesting a 19.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for OMI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 9, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Nov 3, 2025 | UBS | Kevin Caliendo | Neutral | Downgrade | $4.00 |
| Aug 27, 2025 | JP Morgan | Lisa Gill | Underweight | Maintains | $6.00 |
| Aug 13, 2025 | UBS | Kevin Caliendo | Buy | Maintains | $7.00 |
| Aug 12, 2025 | Baird | Eric Coldwell | Outperform | Maintains | $7.00 |
| Aug 12, 2025 | B of A Securities | Allen Lutz | Underperform | Maintains | $4.75 |
| Aug 12, 2025 | Citigroup | Daniel Grosslight | Buy | Maintains | $7.00 |
| Jun 6, 2025 | Baird | Eric Coldwell | Neutral | Maintains | $10.00 |
| Apr 17, 2025 | Citigroup | Daniel Grosslight | Buy | Maintains | $11.00 |
| Mar 10, 2025 | JP Morgan | Michael Minchak | Underweight | Maintains | $10.00 |
| Mar 3, 2025 | Baird | Eric Coldwell | Neutral | Maintains | $11.00 |
| Feb 25, 2025 | Baird | Eric Coldwell | Neutral | Maintains | $10.00 |
| Feb 13, 2025 | UBS | Kevin Caliendo | Buy | Maintains | $13.00 |
| Feb 4, 2025 | Baird | Eric Coldwell | Neutral | Maintains | $14.00 |
| Nov 5, 2024 | Barclays | Steven Valiquette | Equal-Weight | Maintains | $14.00 |
| Nov 5, 2024 | Citigroup | Daniel Grosslight | Buy | Maintains | $18.50 |
| Nov 5, 2024 | UBS | Kevin Caliendo | Buy | Maintains | $25.00 |
| Nov 5, 2024 | Baird | Eric Coldwell | Neutral | Maintains | $14.00 |
| Aug 21, 2024 | JP Morgan | Lisa Gill | Underweight | Maintains | $18.00 |
| Aug 5, 2024 | Barclays | Steven Valiquette | Equal-Weight | Maintains | $18.00 |
The following stocks are similar to Owens & Minor based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Distributes medical and surgical supplies globally.
Owens & Minor generates revenue primarily through the distribution of medical and surgical supplies to healthcare providers. The company also earns income by offering proprietary products, including surgical kits and custom procedure trays, which enhance its product offerings and cater to the specific needs of surgical settings.
Headquartered in Mechanicsville, Virginia, Owens & Minor is integral to the healthcare supply chain, supporting hospitals, health networks, and other organizations. The company emphasizes improving healthcare delivery and operational efficiency, ensuring critical supplies are consistently available to maintain high-quality healthcare services.
Healthcare
Medical Distribution
23,200
Mr. Edward A. Pesicka
United States
1988
Owens & Minor, Inc. has sold its Products & Healthcare Services segment and brand to Platinum Equity, renaming itself Accendra Health, Inc. as it shifts focus to home-based care.
Owens & Minor's sale of its P&HS segment and rebranding to Accendra Health signals a strategic shift towards home-based care, potentially affecting growth prospects and market valuation.
Owens & Minor, Inc. (NYSE: OMI) will change its name to Accendra Health, Inc. effective December 31, 2025, to align with its focus on the home-based care market.
Owens & Minorโs name change to Accendra Health reflects a strategic shift towards home-based care, signaling potential growth opportunities and a focus on evolving healthcare markets.
Owens & Minor, Inc. (OMI) presented at the Citi Annual Global Healthcare Conference 2025, discussing its strategies and performance. Further details can provide insights into its market position.
Owens & Minor's presentation at a prominent healthcare conference may signal strategic plans or insights, influencing investor sentiment and potential stock performance in the healthcare sector.
Owens & Minor, Inc. (NYSE: OMI) management will participate in the Citi 2025 Global Healthcare Conference on December 2, 2025, with a fireside chat at 2:30 PM ET.
Management participation in investor conferences signals transparency and potential growth insights, which can influence investor confidence and stock performance.
Owens & Minor, Inc. (OMI) will host its Q3 2025 Earnings Call on October 30, 2025, at 5:00 PM EDT, featuring key executives and analysts from major financial firms.
Owens & Minor's Q3 earnings call indicates financial performance insights, guiding investment decisions and market sentiment regarding the companyโs growth and operational health.
Owens & Minor, Inc. (NYSE: OMI) reported Q3 2025 results, focusing on continuing operations post-sale of its Products & Healthcare Services segment, aligning with its strategic pivot.
Owens & Minor's divestiture signals a strategic shift, potentially impacting future revenue streams and operational focus, which could influence stock performance and investor sentiment.
Based on our analysis of 16 Wall Street analysts, Owens & Minor Inc. (OMI) has a median price target of $5.50. The highest price target is $7.00 and the lowest is $4.00.
According to current analyst ratings, OMI has 1 Buy ratings, 2 Hold ratings, and 2 Sell ratings. The stock is currently trading at $3.36. Always conduct your own research and consider your investment goals before making investment decisions.
Wall Street analysts predict OMI stock could reach $5.50 in the next 12 months. This represents a 63.7% increase from the current price of $3.36. Please note that this is a projection by Wall Street analysts and not a guarantee.
Owens & Minor generates revenue primarily through the distribution of medical and surgical supplies to healthcare providers. The company also earns income by offering proprietary products, including surgical kits and custom procedure trays, which enhance its product offerings and cater to the specific needs of surgical settings.
The highest price target for OMI is $7.00 from Kevin Caliendo at UBS, which represents a 108.3% increase from the current price of $3.36.
The lowest price target for OMI is $4.00 from Kevin Caliendo at UBS, which represents a 19.0% increase from the current price of $3.36.
The overall analyst consensus for OMI is neutral. Out of 16 Wall Street analysts, 1 rate it as Buy, 2 as Hold, and 2 as Sell, with a median price target of $5.50.
Stock price projections, including those for Owens & Minor Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.